¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"basement membrane antigen"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
¿µ¹® plasma membrane ÇÑ±Û ÇüÁú¸·
¼³¸í   
  ¿øÇüÁú Ç¥¸éÀ» µ¤´Â ¿¯Àº¸·. µÎ²²´Â 5~25¥ìmÀÌ´Ù. ±¤ÇÐÇö¹Ì°æÀ¸·Î´Â °üÂûÇÒ ¼ö ¾øÁö¸¸ ÀüÀÚÇö¹Ì°æÀ¸·Î °üÂûÀÌ °¡´ÉÇÏ´Ù. ¿øÇüÁú¸·ÀÇ ºÐÀÚ±¸Á¶´Â ·¹½ÃƾÀ̳ª ÄÝ·¹½ºÅ×·Ñ µîÀǠǥ¸é È°¼º¹°Áú ºÐÀÚ°¡ 2ºÐÀÚÃþÀ¸·Î ±× Ç¥¸é¿¡ ¹è¿­µÇ¸ç, À̰ÍÀ» °¢ 1ºÐÀÚÃþÀÇ ´Ü¹éÁú ºÐÀÚ°¡ ¾çÂÊ¿¡¼­ »÷µåÀ§Ä¡ÇÑ ´ÜÀ§¸· ±¸Á¶ÀÌ´Ù. ÀüÀÚÇö¹Ì°æÀûÀ¸·Î ÀÌ ´ÜÀ§´Â ¾Ï-¸í-¾ÏÀÇ 3Ãþ(°¢ ¾à 20nm)À¸·Î ±¸º°µÈ´Ù. ¿øÇüÁúÀÇ Åõ°ú¼º¿¡ Áß¿äÇÑ ±¸½ÇÀ» Çϸç, »ý¸®»óŰ¡ º¯Çϸ頱נÅõ°ú¼ºµµ ½Å¼ÓÈ÷ º¯ÇÑ´Ù. ¶Ç, ¼Õ»óÀÌ µÇ¸é ½±°Ô »õ·Î Çü¼ºµÈ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antigen receptor
    Ç׿ø¼ö¿ëü
  • antigen recognition
    Ç׿øÀνÄ
  • antigen-antibody complex
    Ç׿øÇ×üº¹ÇÕü
  • antigen-antibody interaction
    Ç׿øÇ×ü»óÈ£ÀÛ¿ë
  • antigen-antibody reaction
    Ç׿øÇ×ü¹ÝÀÀ
  • antigen-binding site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-combining site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-presenting cell
    Ç׿øÁ¦½Ã¼¼Æ÷
  • antigen-reactive cell
    Ç׿ø¹ÝÀÀ¼¼Æ÷
  • antigen-recognition site
    Ç׿øÀÎÁöºÎÀ§
  • antigen-recognizing cell
    Ç׿øÀÎÁö¼¼Æ÷
  • avidin-antigen conjugate
    ¾ÆºñµòÇ׿øÁ¢ÇÕü
  • capsid antigen
    ĸ½ÃµåÇ׿ø
  • capsular antigen
    ÇǸ·Ç׿ø
  • common antigen
    °øÅëÇ׿ø
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antigen-antibody reaction
    Ç׿øÇ×ü¹ÝÀÀ
  • antigen-binding site
    Ç׿ø°áÇÕºÎÀ§
  • hyaline membrane disease
    À¯¸®Áú¸·º´
  • membrane
    ¸·
  • amnionic membrane
    ¾ç¸·
  • arachnoid membrane
    °Å¹Ì¸·
  • mucous membrane
    Á¡¸·
  • nuclear membrane
    ÇÙ¸·
  • periorbital membrane
    (¢¡ periorbita) ´«È®»À¸·, ¾È¿Í°ñ¸·
  • plasma membrane
    ÇüÁú¸·
  • semipermeable membrane
    ¹ÝÅõ¸·
  • serous membrane
    À帷
  • slit membrane
    Æ´»õ¸·
  • spiral membrane
    ³ª¼±¸·, °í½Ç°è´Üº®
  • synovial membrane
    À±È°¸·
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antigen diffusion constant
    Ç׿øÈ®»ê»ó¼ö
  • antigen excess zone
    Ç׿ø°úÀ×±¸¿ª
  • antigen-antibody complex
    Ç׿øÇ×üº¹ÇÕü
  • antigen-antibody interaction
    Ç׿øÇ×ü¹ÝÀÀ
  • antigen-antibody reaction
    Ç׿øÇ×ü¹ÝÀÀ
  • antigen-binding site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-combining site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-presenting cell
    Ç׿øÀü´Þ¼¼Æ÷
  • antigen-reactive cell
    Ç׿ø¹ÝÀÀ¼¼Æ÷
  • antigen-recognition site
    Ç׿øÀÎÁöºÎÀ§
  • antigen-recognizing cell
    Ç׿øÀÎÁö¼¼Æ÷
  • avidin-antigen conjugate
    ¾ÆºñµòÇ׿øÁ¢ÇÕü
  • capsid antigen
    ĸ½ÃµåÇ׿ø
  • capsular antigen
    ÇǸ·Ç׿ø
  • circumsporozoite antigen
    Æ÷ÀÚ¼ÒüÇ׿ø
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • acid, membrane teichoic
    ¸·¼ºÅ¸ÀÌÄÚ»ê
  • acrosomal membrane
    ÷´Üü¸·
  • amnionic membrane
    ¾ç¸·.
  • anal membrane
    Ç×¹®¸·
  • antebrachial interosseous membrane
    ¾Æ·¡ÆÈ»À»çÀ̸·
  • anterior atlanto-occipital membrane
    ¾ÕȯÃßÈĵθ·, ÀüȯÃßÈĵθ·(îñü» õÐý­Ô騝
  • anterior atlanto-occipital membrane
    ¾Õ°í¸®µÚÅë¼ö¸·
  • anterior hyaloid membrane
    ¾ÕÀ¯¸®Ã¼¸·
  • anterior limiting membrane
    ¾Õ°æ°èÆÇ
  • anterior vitreous membrane
    ¾Õ(Àü)À¯¸®Ã¼¸·
  • artificial membrane
    Àΰø¸·(Àΰø¸·).
  • glassy membrane
    À¯¸®¸·.
  • glomerular membrane
    »ç±¸Ã¼¸·(¡­Ø¯).
  • glomerular membrane
    »ç±¸Ã¼¸·.
  • hemochorial membrane
    Ç÷¾×À¶¸ð¸·
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • a antigen
    A Ç׿ø
  • accessible antigen
    Á¢±Ù°¡´ÉÇ׿ø, ±ÙÁ¢Ç׿ø(ÐÎïÈù÷ê«).
  • analysis, antigen
    Ç׿øºÐ¼®
  • anti-extractable nuclear antigen
    Ç×-ÃßÃ⼺ ÇÙÇ׿ø
  • antigen
    Ç׿ø(ù÷ê«)
  • antigen
    Ç׿ø(ù÷ê«)
  • antigen
    Ç׿ø
  • antigen antibody interaction
    Ç׿øÇ×ü»óÈ£¹ÝÀÀ.
  • antigen antibody interaction
    Ç׿øÇ×ü»óÈ£¹ÝÀÀ.
  • antigen antibody interaction
    Ç׿øÇ×ü»óÈ£¹ÝÀÀ.
  • antigen binding capacity
    Ç׿ø°áÇÕ´É(¡­Ì¿ùêÒö).
  • antigen binding fragment
    Ç׿ø°áÇÕºÎÀ§
  • antigen binding receptor
    Ç׿ø°áÇÕ¼ö¿ëü
  • antigen binding site
    Ç׿ø°áÇÕºÎÀ§
  • antigen capture assay
    Ç׿øÆ÷È¹ÃøÁ¤
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Umbo of tympanic membrane
    °í¸·¹è²Å
    [¿¾ ¿ë¾î] °í¸·Á¦
  • Recesses of tympanic membrane
    °í¸·¿À¸ñ
    [¿¾ ¿ë¾î] °í¸·ÇÔ¿ä
  • Tympanic wall [Spiral membrane]
    °í½Ç°è´Üº® [³ª¼±¸·]
    [¿¾ ¿ë¾î] °í½Çº®
  • Tympanic wall of cochlear duct [Spiral membrane]
    °í½Ç°è´Üº® [³ª¼±¸·]
    [¿¾ ¿ë¾î] °í½Ç°èº®
  • Mucous membrane of tympanic cavity
    °í½ÇÁ¡¸·
    [¿¾ ¿ë¾î] °í½ÇÁ¡¸·
  • Reticular membrane
    ±×¹°¸·
    [¿¾ ¿ë¾î] ¼¼¸Á¸·
  • Vitelline membrane
    ³­È²¸·
    [¿¾ ¿ë¾î] ³­È²¸·
  • Endothelioendothelial membrane
    ³»ÇÇ»çÀ̸·
    [¿¾ ¿ë¾î] ³»Çǰ£¼ºÇ÷°£°³À縷
  • Endotheliochorial membrane
    ³»ÇÇÀ¶¸ð¸·
    [¿¾ ¿ë¾î] ³»ÇÇÀ¶¸ð¸·¼ºÇ÷°£°³À縷
  • Quadrangular membrane
    ³×¸ð¸·
    [¿¾ ¿ë¾î] »ç°¢¸·
  • Periventricular glial limiting membrane
    ³ú½ÇÁÖÀ§¾Æ±³°æ°è¸·
    [¿¾ ¿ë¾î] ³ú½ÇÁÖÀ§°æ°è¸·
  • Tectorial membrane
    µ¤°³¸·
    [¿¾ ¿ë¾î] °³¸·
  • Tectorial membrane
    µ¤°³¸·
    [¿¾ ¿ë¾î] Çǰ³¸·
  • Pupillary membrane
    µ¿°ø¸·
    [¿¾ ¿ë¾î] µ¿°ø¸·
  • Secondary tympanic membrane
    µÑ°°í¸·
    [¿¾ ¿ë¾î] Á¦ÀÌ°í¸·
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • membrane hydrolysis
    ¸·°¡¼öºÐÇØ(دʥâ©ÝÂú°)
  • membrane mimetic chemistry
    À¯»ç(×¾ÞÄ) ¸·È­ÇÐ(دûùùÊ)
  • membrane osmometer
    ¸·»ïÅõ°è(د߶÷âͪ)
  • membrane resistance
    ¸·ÀúÇ×(دî½ù÷)
  • membrane potential
    ¸·ÀüÀ§(دï³êÈ)
  • membrane structure
    ¸·±¸Á¶(دϰðã)
  • membrane transport
    ¸·À̵¿(دì¹ÔÑ)
  • membrane trigger hypothesis
    ¸·À¯¹ß¼³(دë¯Û¡àã)
  • mucous membrane
    Á¡¾×¸·(ïÄäûد)
  • outer membrane
    ¿Ü¸·(èâØ¯)
  • permselective membrane
    ¼±ÅÃÅõ°ú¸·(àÔ÷É÷âΦد)
  • plasma membrane
    ¿øÇüÁú¸·(ê«û¡òõد)
  • precipitation membrane
    ħÀü¸·(öØîþد)
  • protoplast membrane
    ¿øÇüÁúü¸·(د)
  • purple membrane
    ÀÚ»ö¸·(í¹ß䨝)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
SCM Schwann cell membrane; sensation, circulation, and motion; Society of Computer Medicine; soluble cyt...
BM   1) Bone Marrow
  2) Basement Membrane
  3) Bench-Mark; ¼öÁØ ±âÇ¥...
BMZ Basement Membrane Zone
GBM Glomerular Basement Membrane
ABM adjusted body mass; alveolar basement membrane; autologous bone marrow
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
GBM Glomerular basement membrane
TBMD Thin basement membrane disease
TBM Tubular basement membrane
RBM reconstituted basement membrane
AMA-1 Apical Membrane Antigen-1
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • antigen presentation
    Ç׿ø Á¦°ø, Ç׿ø Àü´Þ, Ç׿ø Á¦½Ã
  • antigen processing
    Ç׿ø ó¸®
    Ç׿øÀÌ Ç׿ø Á¦½Ã ¼¼Æ÷¿¡ ÀÇÇÏ¿© Æ÷ÃËµÇ°í ³ª¼­ B ¼¼Æ÷, T ¼¼Æ÷¿¡ Ç׿øÀÌ Á¦½ÃµÇ±â±îÁöÀÇ °úÁ¤À» ¸»ÇÑ´Ù. ÀÌ °úÁ¤¿¡´Â Ç׿øÀÇ Å½½Ä, Ç׿øÀÇ ´ÜÆíÈ­ ȤÀº Ç׿ø °áÁ¤±â±îÁöÀÇ ºÐÇØ 󸮰¡ Æ÷ÇԵȴÙ.
  • antigen receptor
    Ç׿ø ¼ö¿ëü
  • antigen recognition site
    Ç׿ø ½Äº°ºÎ
  • antigen shift
    Ç׿ø ´ëº¯ÀÌ
  • antigen unit
    Ç׿ø ´ÜÀ§
  • antigen-antibody reaction
    Ç׿ø-Ç×ü ¹ÝÀÀ
  • carcinoembryonic antigen assay
    ¾Ï ¹è¾Æ¼º Ç׿ø ÃøÁ¤, ¾Ï¼º ¹è¾Æ¼º Ç׿ø ÃøÁ¤
  • class I human leukocyte antigen
    Á¦ 1±Þ ÀÎü ¹éÇ÷±¸ Ç׿ø
  • class II human leukocyte antigen
    Á¦ 2±Þ ÀÎü ¹éÇ÷±¸ Ç׿ø
  • dander antigen
    Àμ³ Ç׿ø
    ÇǺÎÀÇ Ç¥¸éÀ¸·ÎºÎÅÍ ²÷ÀÓ¾øÀÌ »êÆ÷µÇ°í ÀÖ´Â ¹°ÁúÀÇ È¥ÇÕ¹°. ¹Ú¸®µÈ »óÇÇ ¼¼¹Î, ÅÐÀÇ ´ÜÆí, ÇǺÎÀÇ Áö¹æ µîÀÌ Æ÷ÇԵǴµ¥ ƯÈ÷ Àμ³ÀÌ Áß¿äÇÏ´Ù. ¾ÆÅäÇǰ¡ ÀÖ´Â »ç¶÷¿¡¼­´Â Áï½ÃÇü °ú¹ÎÁõÀÇ ¿øÀÎÀÌ µÇ´Â ¼ö°¡ ÀÖ´Ù.
  • determinant antigen
    Ç׿ø °áÁ¤±º, °áÁ¤ Ç׿ø
    ¸é¿ªÇÐÀû ƯÀ̼ºÀ» °áÁ¤Çϴ ƯÁ¤ÀÇ È­ÇÐÀûÀÎ ºÐÀÚ±º.
  • diego antigen
    µð¿¡°í Ç׿ø
  • differentiation antigen
    ºÐÈ­ Ç׿ø
    ¼¼Æ÷°¡ ºÐÈ­ÇØ °¡´Âµ¥ À־ Ç¥ÇöµÇ´Â ¼¼Æ÷¸· »óÀÇ Ç׿ø. T ¼¼Æ÷¿¡¼­´Â B ¼¼Æ÷·ÎºÎÅÍ ±¸º°ÇÏ´Â ºÐÈ­ Ç׿øÀº mouse »çÀÌ¿¡¼­ ¼¼Æ÷¸¦ Åõ¿©ÇÏ¿© ¸¸µé¾îÁø µ¿Á¾ Ç×Ç÷û¿¡ ÀÇÇÏ¿© °ËÃâµÇ´Â Ç׿ø
  • DR antigen
    DR Ç׿ø
    HLA-D ¿µ¿ª À¯ÀüÀÚÀÇ Áö¹è¸¦ ¹Þ´Â Ç׿øÀ̸ç, ÁÖ·Î B ¼¼Æ÷ ¹× macro
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
antigen excess In a precipitation test, the presence of uncombined antigen above that required to combine with all of the antibody; precipitation may be inhibited because the presence of excess antigen gives rise to soluble antigen-antibody complexes, in vivo the resultant antigen-antibody interaction in such an antigen excess may give rise to immune complexes, which have a potential to induce cellular damage; such injury underlies the pathologic changes seen in certain immune complex diseases.
(05 Mar 2000)
antigen interferon <cytokine> Interferon elaborated by T lymphocytes in response to either specific antigen or mitogenic stimulation.
This type II interferon can be produced by recombinant DNA technology and is similar to the interferon secreted by lymphocytes and has antiviral and antineoplastic activity.
Synonym: antigen interferon, immune interferon.
Pharmacological action: antineoplastic agent, antiviral agents.
(20 Sep 2002)
antigen p150,95 A major adhesion-associated heterodimer molecule expressed by human monocytes, granulocytes, nk cells, and some lymphocytes. The alpha subunit is the CD11c antigen (also called leu-m5), a surface antigen expressed on some myeloid cells. The beta subunit is the CD18 antigen (antigens, CD18). The p150,95 antigen has been shown to play an important role in cell-cell and cell-substrate adhesive interactions.
(12 Dec 1998)
antigen presentation A cell that carries on its surface antigen bound to MCH Class I or Class II molecules and presents the antigen in this context to T-cells. Includes macrophages, endothelium, dendritic cells and Langerhans cells of the skin.
See: MHC restriction, histocompatibility antigens.
(18 Nov 1997)
antigen presenting cell A cell that carries on its surface antigen bound to MCH Class I or Class II molecules and presents the antigen in this context to T-cells. Includes macrophages, endothelium, dendritic cells and Langerhans cells of the skin.
See: MHC restriction, histocompatibility antigens.
(18 Nov 1997)
antigen-presenting cells Immunocompetent cells, usually ia positive, that mediate the cellular immune response by processing and presenting antigens or mitogens which stimulate T-cell activation.
(12 Dec 1998)
antigen processing Modification of an antigen by accessory cells. This usually involves endocytosis of the antigen and either minimal cleavage or unfolding. The processed antigen is then presented in modified form by the accessory cell.
(18 Nov 1997)
antigen-responsive cell A small lymphocyte that, although not itself an immunologically activated cell, responds to antigenic (immunogenic) stimulus by a process of division and differentiation that results in the production of immunologically activated cells.
Synonym: antigen-responsive cell.
(05 Mar 2000)
antigen-sensitive cell A small lymphocyte that, although not itself an immunologically activated cell, responds to antigenic (immunogenic) stimulus by a process of division and differentiation that results in the production of immunologically activated cells.
Synonym: antigen-responsive cell.
(05 Mar 2000)
antigen shift Abrupt change in antigens expressed by a species or variety of organisms. Usually seen in microorganisms where the change may allow escape from immune recognition. Antigenic drift is a more gradual change.
See: antigenic variation.
(18 Nov 1997)
antigen unit The smallest amount of antigen that, in the presence of specific antiserum, will fix 1 complement unit.
(05 Mar 2000)
aspergillus antigen skin test <investigation> An antigen, prepared from aspergillus, is injected into the skin. In 48 to 72 hours the site is read as positive or negative. A positive skin test (inflammation at the test site) indicates prior exposure to aspergillus and therefore a risk for developing aspergillosis.
(27 Sep 1997)
Au antigen Auberger blood group
Aus antigen <virology> An envelope antigen now known as HBsAg of Hepatitis B virus. Appearance of the antigen in serum is associated with a phase of high infectivity.
(18 Nov 1997)
Australia antigen <virology> An envelope antigen now known as HBsAg of Hepatitis B virus. Appearance of the antigen in serum is associated with a phase of high infectivity.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á